Menu
Live
Market Overview
Live indices, gainers & losers
Market Pulse
AI-curated live updates
Market Movers
Top gainers & losers by cap
Market Signals
Value, momentum & analyst signals
Smart Money
Insider & congress trades
Hedge Funds
What 63 elite funds bought & sold
52-Week Highs
Stocks breaking out to new highs
52-Week Lows
Beaten-down stocks near support
High Beta
Stocks that move more than the market
Earnings Calendar
Upcoming earnings dates
Daily
Research
Invest
LIVE
GRAIL Inc.
GRAL
NASDAQ·Healthcare·Biotechnology·Mkt cap $2.9B
$68.55
▲ +0.65%
View full research view
Our plain-language verdict, the thesis, risk factors, and what is changing about the business.
View research view52-Week Range
$29.95 - $118.84
P/E
Fwd P/E
Beta
Div Yield
Avg Vol
Shares Out
Mkt Cap
Price action
Price chart
Up 43.2% over the trailing year
Total returns
Price performance
Total return across standard periods - splits & dividends adjusted by FMP. Periods longer than 1Y show annualized in the tooltip.
Why we rate it this way
The thesis at a glance
Bull and bear case · plain-English context across the five lenses we evaluate.
Bull Case
4 reasons
- Multi-cancer detection capability in single blood test
- Advanced genomic sequencing and AI-driven analysis platform
- Illumina heritage providing access to cutting-edge sequencing technology
- Large clinical validation datasets supporting test accuracy and reliability
Bear Case
1 risk
- Very high volatility (beta 3.2). Expect 3x market swings. Position size accordingly.
Growth
Moderate growth ahead
Expanding addressable market for cancer screening in aging populations
Value
Deep value opportunity - significant discount to Life Sciences Tools peers
Momentum
Hot
+23.9% over 3m
Quality
Loss-making
Solid business
Dividend
None
No dividend
Smart-money signal
Who's buying GRAL right now
Insider Form 4s, 13F institutional filings, and Congressional disclosures - at a glance.
Earnings track record
Latest print - beat on both lines
AI-summarized recap of last quarter, plus the surprise on every print.
Next: May 12, 2026
MAY 5, 2026
Reported EPS of -$2.29 vs -$2.76 consensus (+17.1% surprise). Revenue of $40.8M vs $39.2M expected (+4.2%). Beat on both top and bottom lines.
EPS surprise · last 4Q
1 of 1 beats
Q2 26
+17.1%
Next: May 12, 2026
Revenue trend · last 8Q
—
—
+26%
+19%
+11%
+26%
+14%
+28%
Q2 24
Q3 24
Q4 24
Q1 25
Q2 25
Q3 25
Q4 25
Q1 26
$32.0M
$28.7M
$38.3M
$31.8M
$35.5M
$36.2M
$43.6M
$40.8M
Margins · last 8Q
Gross
—
Profit
-228.5%
Wall Street consensus
6 analysts · 67% Buy
Live ratings and price targets aggregated across covering analysts.
Buy
67%
Hold
33%
Sell
0%
Median Price Target
$57.00
▼ -16.8% vs $68.55
Latest: TD Cowen · May 6, 2026
3 analysts covering